Analysts HC Wainwright, BTIG Research, and Royal Bank of Canada reaffirm/raise "Buy" ratings and target prices for Verastem and Vera Therapeutics.

Verastem's (VSTM) "Buy" rating is reaffirmed by HC Wainwright, setting a $17.50 target price. BTIG Research also restates a "Buy" rating with a $27.00 target price, while Royal Bank of Canada issues an "Outperform" rating with a $32.00 target price. Meanwhile, Vera Therapeutics (NASDAQ:VERA) target price is raised by Wedbush from $21.00 to $34.00, maintaining a "Neutral" rating. These analyst actions come in addition to coverage from firms such as Cantor Fitzgerald and Oppenheimer.

March 23, 2024
3 Articles